Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial

Giugliano, Robert P.; Pedersen, Terje R.; Park, Jeong-Gun; De Ferrari, Gaetano M.; Gaciong, Zbigniew A.; Ceska, Richard; Toth, Kalman; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Schiele, François; Mach, François; Ott, Brian R.; Kanevsky, Estella; Pineda, Armando Lira; Somaratne, Ransi; Wasserman, Scott M.; Keech, Anthony C.; Sever, Peter S.; Sabatine, Marc S.